| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 324 | 2023 | 15694 | 10.510 |
Why?
|
| Mastectomy, Segmental | 82 | 2020 | 1026 | 6.220 |
Why?
|
| Mastectomy | 69 | 2020 | 1534 | 4.670 |
Why?
|
| Neoplasm Recurrence, Local | 102 | 2021 | 10035 | 3.400 |
Why?
|
| Radiation Oncology | 16 | 2022 | 529 | 3.100 |
Why?
|
| Radiotherapy, Adjuvant | 68 | 2023 | 2231 | 2.870 |
Why?
|
| Lymphatic Metastasis | 77 | 2020 | 4844 | 2.720 |
Why?
|
| Neoadjuvant Therapy | 56 | 2019 | 4975 | 2.480 |
Why?
|
| Receptors, Estrogen | 30 | 2020 | 2086 | 2.390 |
Why?
|
| Carcinoma, Ductal, Breast | 34 | 2016 | 1216 | 2.210 |
Why?
|
| Chemotherapy, Adjuvant | 71 | 2020 | 3890 | 2.090 |
Why?
|
| Radiotherapy | 31 | 2018 | 1824 | 1.980 |
Why?
|
| Lymph Nodes | 35 | 2022 | 2967 | 1.840 |
Why?
|
| Female | 369 | 2023 | 141928 | 1.790 |
Why?
|
| Lymphatic Irradiation | 11 | 2019 | 133 | 1.760 |
Why?
|
| Neoplasm Staging | 102 | 2019 | 13658 | 1.730 |
Why?
|
| Axilla | 37 | 2022 | 902 | 1.690 |
Why?
|
| Inflammatory Breast Neoplasms | 17 | 2015 | 509 | 1.680 |
Why?
|
| Radiotherapy Dosage | 50 | 2017 | 3842 | 1.670 |
Why?
|
| Breast | 25 | 2023 | 1344 | 1.560 |
Why?
|
| Receptors, Progesterone | 17 | 2020 | 1392 | 1.540 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 26 | 2015 | 2370 | 1.500 |
Why?
|
| Humans | 408 | 2023 | 261506 | 1.400 |
Why?
|
| Tamoxifen | 14 | 2020 | 876 | 1.400 |
Why?
|
| Lymph Node Excision | 28 | 2022 | 1959 | 1.400 |
Why?
|
| Receptor, ErbB-2 | 28 | 2020 | 2518 | 1.400 |
Why?
|
| Combined Modality Therapy | 69 | 2019 | 8865 | 1.360 |
Why?
|
| Radiation Injuries | 13 | 2018 | 1411 | 1.340 |
Why?
|
| SEER Program | 43 | 2016 | 1000 | 1.310 |
Why?
|
| Sentinel Lymph Node Biopsy | 24 | 2019 | 1415 | 1.250 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 13 | 2015 | 674 | 1.210 |
Why?
|
| Middle Aged | 202 | 2021 | 86204 | 1.180 |
Why?
|
| Aged | 197 | 2021 | 70117 | 1.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 47 | 2017 | 15862 | 1.160 |
Why?
|
| Doxorubicin | 26 | 2017 | 3005 | 1.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2015 | 840 | 1.110 |
Why?
|
| Adult | 186 | 2020 | 77950 | 1.090 |
Why?
|
| Disease-Free Survival | 60 | 2019 | 10001 | 1.080 |
Why?
|
| Mammaplasty | 12 | 2018 | 780 | 1.040 |
Why?
|
| Brachytherapy | 13 | 2016 | 977 | 1.030 |
Why?
|
| Radiation Tolerance | 12 | 2016 | 629 | 1.020 |
Why?
|
| Carcinoma, Lobular | 16 | 2015 | 611 | 0.990 |
Why?
|
| Medicare | 25 | 2016 | 860 | 0.980 |
Why?
|
| Retrospective Studies | 96 | 2019 | 37905 | 0.830 |
Why?
|
| Carcinoma | 11 | 2011 | 2578 | 0.810 |
Why?
|
| Treatment Outcome | 85 | 2019 | 32848 | 0.810 |
Why?
|
| United States | 62 | 2022 | 15433 | 0.800 |
Why?
|
| Prognosis | 75 | 2020 | 21713 | 0.800 |
Why?
|
| Radiotherapy, Conformal | 11 | 2019 | 902 | 0.790 |
Why?
|
| Aged, 80 and over | 95 | 2020 | 29902 | 0.780 |
Why?
|
| Radiotherapy, Intensity-Modulated | 12 | 2015 | 2104 | 0.750 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2018 | 2594 | 0.740 |
Why?
|
| Health Services Needs and Demand | 3 | 2016 | 244 | 0.730 |
Why?
|
| Risk Assessment | 32 | 2017 | 6869 | 0.720 |
Why?
|
| Radiotherapy, High-Energy | 6 | 2007 | 295 | 0.720 |
Why?
|
| Radiation-Sensitizing Agents | 8 | 2016 | 363 | 0.710 |
Why?
|
| Survival Analysis | 44 | 2019 | 9180 | 0.710 |
Why?
|
| Antibiotics, Antineoplastic | 7 | 2012 | 726 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 7 | 2015 | 2403 | 0.680 |
Why?
|
| Age Factors | 25 | 2015 | 5377 | 0.660 |
Why?
|
| Neoplasm Metastasis | 21 | 2015 | 5112 | 0.630 |
Why?
|
| Survival Rate | 43 | 2017 | 12221 | 0.630 |
Why?
|
| Antineoplastic Agents | 35 | 2016 | 14289 | 0.610 |
Why?
|
| Paclitaxel | 15 | 2017 | 1996 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 9 | 2018 | 1303 | 0.610 |
Why?
|
| Health Care Costs | 8 | 2016 | 674 | 0.600 |
Why?
|
| Analysis of Variance | 18 | 2015 | 2307 | 0.600 |
Why?
|
| Proportional Hazards Models | 34 | 2016 | 4988 | 0.590 |
Why?
|
| Hypothyroidism | 2 | 2009 | 204 | 0.580 |
Why?
|
| Fast Neutrons | 7 | 1997 | 16 | 0.580 |
Why?
|
| Tumor Burden | 11 | 2017 | 1987 | 0.570 |
Why?
|
| Organ Sparing Treatments | 3 | 2015 | 277 | 0.570 |
Why?
|
| Trastuzumab | 14 | 2017 | 696 | 0.560 |
Why?
|
| Risk Factors | 45 | 2016 | 17523 | 0.560 |
Why?
|
| Multivariate Analysis | 26 | 2015 | 4298 | 0.550 |
Why?
|
| Clavicle | 6 | 2010 | 65 | 0.550 |
Why?
|
| Time Factors | 37 | 2017 | 12926 | 0.550 |
Why?
|
| Clinical Trials as Topic | 15 | 2017 | 3719 | 0.540 |
Why?
|
| Carotid Arteries | 2 | 2008 | 240 | 0.540 |
Why?
|
| NF-kappa B | 3 | 2010 | 1549 | 0.530 |
Why?
|
| Follow-Up Studies | 41 | 2019 | 14889 | 0.530 |
Why?
|
| Consensus | 7 | 2022 | 978 | 0.520 |
Why?
|
| Patient Selection | 14 | 2015 | 2055 | 0.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 13 | 2015 | 3251 | 0.510 |
Why?
|
| Biomarkers, Tumor | 22 | 2018 | 10331 | 0.490 |
Why?
|
| Veterans | 2 | 2022 | 1641 | 0.490 |
Why?
|
| Neoplasm Invasiveness | 16 | 2015 | 3981 | 0.480 |
Why?
|
| Lymphedema | 4 | 2014 | 239 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2015 | 7551 | 0.470 |
Why?
|
| Fluorouracil | 14 | 2017 | 1944 | 0.470 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2008 | 388 | 0.470 |
Why?
|
| Forestry | 1 | 2013 | 3 | 0.460 |
Why?
|
| Risk Management | 2 | 2014 | 107 | 0.460 |
Why?
|
| Conservation of Natural Resources | 1 | 2013 | 17 | 0.450 |
Why?
|
| Cohort Studies | 28 | 2015 | 9244 | 0.450 |
Why?
|
| Hospice Care | 5 | 2015 | 156 | 0.450 |
Why?
|
| Neoplasm Proteins | 4 | 2010 | 3230 | 0.450 |
Why?
|
| Gene Expression | 7 | 2016 | 3570 | 0.440 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 672 | 0.440 |
Why?
|
| Forecasting | 5 | 2016 | 694 | 0.440 |
Why?
|
| Regression Analysis | 9 | 2015 | 1546 | 0.440 |
Why?
|
| Prospective Studies | 31 | 2019 | 12873 | 0.440 |
Why?
|
| Mastectomy, Modified Radical | 7 | 2014 | 70 | 0.430 |
Why?
|
| Centromere Protein B | 1 | 2012 | 5 | 0.430 |
Why?
|
| Boron Neutron Capture Therapy | 4 | 1997 | 10 | 0.430 |
Why?
|
| Professional-Patient Relations | 1 | 2013 | 124 | 0.430 |
Why?
|
| Neoplasms | 17 | 2022 | 15193 | 0.430 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 915 | 0.410 |
Why?
|
| Inflammation | 8 | 2019 | 2522 | 0.400 |
Why?
|
| Logistic Models | 15 | 2016 | 3441 | 0.400 |
Why?
|
| Healthcare Disparities | 3 | 2014 | 598 | 0.400 |
Why?
|
| Tissue Expansion | 2 | 2011 | 71 | 0.400 |
Why?
|
| Seminoma | 2 | 2004 | 81 | 0.400 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2012 | 362 | 0.390 |
Why?
|
| Models, Statistical | 3 | 2016 | 1171 | 0.390 |
Why?
|
| Head and Neck Neoplasms | 7 | 2016 | 3976 | 0.390 |
Why?
|
| Medical Errors | 1 | 2013 | 219 | 0.380 |
Why?
|
| Autoantigens | 1 | 2012 | 234 | 0.380 |
Why?
|
| Positron-Emission Tomography | 6 | 2015 | 2173 | 0.380 |
Why?
|
| Surgical Flaps | 6 | 2018 | 927 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2008 | 1493 | 0.370 |
Why?
|
| Radiometry | 2 | 2013 | 980 | 0.360 |
Why?
|
| Arm | 2 | 2018 | 147 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2016 | 5437 | 0.360 |
Why?
|
| Taxoids | 10 | 2015 | 967 | 0.350 |
Why?
|
| Dose-Response Relationship, Radiation | 7 | 2013 | 726 | 0.350 |
Why?
|
| Insurance, Physician Services | 1 | 2009 | 7 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2019 | 6207 | 0.350 |
Why?
|
| Incidence | 17 | 2016 | 5673 | 0.340 |
Why?
|
| Texas | 16 | 2016 | 6311 | 0.340 |
Why?
|
| Brain Neoplasms | 8 | 2016 | 4849 | 0.340 |
Why?
|
| Odds Ratio | 13 | 2015 | 2316 | 0.340 |
Why?
|
| Patient Positioning | 3 | 2018 | 195 | 0.340 |
Why?
|
| Lung Neoplasms | 15 | 2015 | 11538 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2011 | 2326 | 0.330 |
Why?
|
| ErbB Receptors | 5 | 2015 | 2295 | 0.330 |
Why?
|
| Gene Expression Profiling | 4 | 2011 | 5159 | 0.330 |
Why?
|
| Cost-Benefit Analysis | 5 | 2016 | 945 | 0.320 |
Why?
|
| Anthracyclines | 6 | 2015 | 331 | 0.320 |
Why?
|
| Cyclophosphamide | 14 | 2017 | 3001 | 0.320 |
Why?
|
| Predictive Value of Tests | 11 | 2016 | 4892 | 0.320 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2010 | 1833 | 0.320 |
Why?
|
| Angelman Syndrome | 5 | 1998 | 78 | 0.310 |
Why?
|
| Immunohistochemistry | 11 | 2012 | 7548 | 0.310 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 550 | 0.310 |
Why?
|
| Testicular Neoplasms | 2 | 2004 | 529 | 0.310 |
Why?
|
| Neoplasms, Second Primary | 5 | 2012 | 1350 | 0.310 |
Why?
|
| Registries | 10 | 2015 | 2170 | 0.300 |
Why?
|
| Neoplastic Stem Cells | 7 | 2016 | 1443 | 0.300 |
Why?
|
| Adenocarcinoma | 8 | 2014 | 7789 | 0.290 |
Why?
|
| Minority Groups | 1 | 2009 | 322 | 0.290 |
Why?
|
| Capecitabine | 3 | 2017 | 388 | 0.290 |
Why?
|
| Body Mass Index | 6 | 2012 | 2203 | 0.280 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 176 | 0.280 |
Why?
|
| Professional Competence | 1 | 2007 | 136 | 0.280 |
Why?
|
| Chromatids | 3 | 2012 | 78 | 0.270 |
Why?
|
| Algorithms | 8 | 2017 | 3890 | 0.270 |
Why?
|
| Aromatase Inhibitors | 4 | 2018 | 305 | 0.270 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 295 | 0.270 |
Why?
|
| Radiosurgery | 5 | 2015 | 1330 | 0.260 |
Why?
|
| Male | 56 | 2022 | 123000 | 0.250 |
Why?
|
| Mammography | 7 | 2015 | 1010 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2014 | 479 | 0.250 |
Why?
|
| Phenols | 2 | 2021 | 107 | 0.250 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2021 | 799 | 0.250 |
Why?
|
| Ataxia Telangiectasia | 2 | 2004 | 62 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2008 | 2508 | 0.250 |
Why?
|
| Neoplasm, Residual | 10 | 2019 | 1656 | 0.240 |
Why?
|
| Haplotypes | 4 | 2009 | 856 | 0.240 |
Why?
|
| Radiography | 7 | 2013 | 1904 | 0.240 |
Why?
|
| Quality of Health Care | 4 | 2016 | 621 | 0.240 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2004 | 126 | 0.240 |
Why?
|
| Precancerous Conditions | 2 | 2008 | 1058 | 0.240 |
Why?
|
| Abortion, Habitual | 1 | 2003 | 24 | 0.240 |
Why?
|
| Young Adult | 25 | 2019 | 21445 | 0.240 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2019 | 1215 | 0.230 |
Why?
|
| DNA Repair | 5 | 2014 | 1872 | 0.230 |
Why?
|
| Prader-Willi Syndrome | 3 | 1998 | 69 | 0.230 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 65 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2015 | 5319 | 0.230 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 80 | 0.230 |
Why?
|
| BRCA2 Protein | 3 | 2004 | 358 | 0.230 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2013 | 1226 | 0.220 |
Why?
|
| Databases, Factual | 7 | 2016 | 2218 | 0.220 |
Why?
|
| Medical Oncology | 4 | 2014 | 1423 | 0.220 |
Why?
|
| Confidence Intervals | 6 | 2019 | 756 | 0.220 |
Why?
|
| Postoperative Care | 3 | 2014 | 739 | 0.220 |
Why?
|
| Spermatogenesis | 1 | 2004 | 308 | 0.220 |
Why?
|
| Coronary Vessels | 2 | 2011 | 665 | 0.210 |
Why?
|
| Carcinoma in Situ | 5 | 2013 | 487 | 0.210 |
Why?
|
| DNA Damage | 4 | 2007 | 1954 | 0.210 |
Why?
|
| Chi-Square Distribution | 7 | 2015 | 1323 | 0.210 |
Why?
|
| Signal Transduction | 10 | 2016 | 11965 | 0.210 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 644 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 2 | 2022 | 348 | 0.210 |
Why?
|
| Fertility | 1 | 2004 | 336 | 0.210 |
Why?
|
| Cranial Irradiation | 3 | 2015 | 315 | 0.210 |
Why?
|
| Risk | 8 | 2014 | 1972 | 0.210 |
Why?
|
| Curriculum | 1 | 2007 | 860 | 0.200 |
Why?
|
| Gene Frequency | 2 | 2004 | 1163 | 0.200 |
Why?
|
| Indazoles | 2 | 2014 | 297 | 0.200 |
Why?
|
| Lymphocytes | 4 | 2012 | 1234 | 0.200 |
Why?
|
| Radionuclide Imaging | 4 | 2009 | 660 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 4549 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2002 | 333 | 0.190 |
Why?
|
| Light | 1 | 2021 | 245 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2003 | 337 | 0.180 |
Why?
|
| Nomograms | 2 | 2013 | 313 | 0.180 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2010 | 46 | 0.180 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2015 | 612 | 0.180 |
Why?
|
| Biopsy, Needle | 5 | 2015 | 1363 | 0.180 |
Why?
|
| BRCA1 Protein | 2 | 2004 | 493 | 0.180 |
Why?
|
| Radiodermatitis | 2 | 2011 | 75 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 1209 | 0.170 |
Why?
|
| Societies, Medical | 4 | 2015 | 1335 | 0.170 |
Why?
|
| Probability | 5 | 2009 | 866 | 0.170 |
Why?
|
| Case-Control Studies | 10 | 2012 | 6100 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 251 | 0.170 |
Why?
|
| Mandibular Neoplasms | 1 | 1999 | 76 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2010 | 342 | 0.160 |
Why?
|
| Sternum | 1 | 2019 | 100 | 0.160 |
Why?
|
| Pneumonia | 1 | 2004 | 751 | 0.160 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2018 | 38 | 0.160 |
Why?
|
| Salivary Gland Neoplasms | 2 | 1994 | 489 | 0.160 |
Why?
|
| Radiation Dosage | 6 | 2008 | 1014 | 0.160 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 3472 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 1429 | 0.160 |
Why?
|
| Iridium Radioisotopes | 2 | 2009 | 56 | 0.160 |
Why?
|
| Ultrasonography, Mammary | 3 | 2015 | 380 | 0.160 |
Why?
|
| Population Surveillance | 3 | 2010 | 627 | 0.160 |
Why?
|
| Anthropometry | 1 | 2018 | 269 | 0.160 |
Why?
|
| Disease Management | 2 | 2016 | 1052 | 0.160 |
Why?
|
| Cell Line, Tumor | 14 | 2016 | 14551 | 0.160 |
Why?
|
| Cell Survival | 8 | 2014 | 3045 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 276 | 0.150 |
Why?
|
| Genes, p53 | 2 | 1999 | 1090 | 0.150 |
Why?
|
| Piperidines | 2 | 2014 | 1035 | 0.150 |
Why?
|
| Stroke | 1 | 2006 | 1144 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2015 | 925 | 0.150 |
Why?
|
| DNA Transposable Elements | 2 | 2012 | 222 | 0.150 |
Why?
|
| Germ-Line Mutation | 2 | 2002 | 1046 | 0.150 |
Why?
|
| Nipples | 4 | 2017 | 132 | 0.150 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 6009 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 88 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2012 | 5178 | 0.150 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 292 | 0.150 |
Why?
|
| Health Care Surveys | 3 | 2011 | 430 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2010 | 2803 | 0.150 |
Why?
|
| Socioeconomic Factors | 4 | 2023 | 1225 | 0.150 |
Why?
|
| Comorbidity | 6 | 2016 | 2352 | 0.150 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cost of Illness | 2 | 2011 | 498 | 0.140 |
Why?
|
| Mastectomy, Radical | 3 | 2005 | 39 | 0.140 |
Why?
|
| Radiation Oncologists | 1 | 2016 | 29 | 0.140 |
Why?
|
| Hospitals, Low-Volume | 1 | 2016 | 53 | 0.140 |
Why?
|
| Phenotype | 7 | 2017 | 6295 | 0.140 |
Why?
|
| Epirubicin | 4 | 2017 | 157 | 0.140 |
Why?
|
| Value-Based Purchasing | 1 | 2016 | 15 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2007 | 1375 | 0.140 |
Why?
|
| Heart | 5 | 2011 | 1223 | 0.140 |
Why?
|
| Gamma Rays | 2 | 2012 | 242 | 0.140 |
Why?
|
| Osteoradionecrosis | 2 | 2012 | 123 | 0.140 |
Why?
|
| Intraoperative Period | 4 | 2015 | 246 | 0.140 |
Why?
|
| Biopsy | 5 | 2012 | 3443 | 0.140 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 77 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2016 | 174 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2016 | 3552 | 0.130 |
Why?
|
| Bone Neoplasms | 3 | 2019 | 2576 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2016 | 1471 | 0.130 |
Why?
|
| Cosmetic Techniques | 1 | 2016 | 73 | 0.130 |
Why?
|
| Receptors, Steroid | 2 | 2014 | 286 | 0.130 |
Why?
|
| Galectin 3 | 1 | 2016 | 138 | 0.130 |
Why?
|
| Terminal Care | 3 | 2015 | 447 | 0.130 |
Why?
|
| Quality of Life | 5 | 2021 | 4532 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 423 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2003 | 2054 | 0.130 |
Why?
|
| Cadherins | 3 | 2016 | 660 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 1064 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2012 | 2232 | 0.120 |
Why?
|
| Wnt Proteins | 2 | 2007 | 397 | 0.120 |
Why?
|
| Carcinoma, Adenoid Cystic | 3 | 1994 | 421 | 0.120 |
Why?
|
| Endocrine System | 1 | 2014 | 36 | 0.120 |
Why?
|
| Expert Testimony | 1 | 2015 | 90 | 0.120 |
Why?
|
| Patient Care Team | 2 | 2013 | 795 | 0.120 |
Why?
|
| Glioma | 2 | 1997 | 1963 | 0.120 |
Why?
|
| Parotid Neoplasms | 2 | 1992 | 148 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2006 | 551 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1374 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 476 | 0.120 |
Why?
|
| Heart Diseases | 2 | 2005 | 732 | 0.120 |
Why?
|
| Radiopharmaceuticals | 4 | 2013 | 1301 | 0.120 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2015 | 167 | 0.120 |
Why?
|
| Phantoms, Imaging | 4 | 2010 | 1271 | 0.120 |
Why?
|
| Melanoma | 3 | 2016 | 5317 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2009 | 222 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 2 | 2016 | 430 | 0.120 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 53 | 0.120 |
Why?
|
| Genetic Variation | 4 | 2013 | 2086 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 5 | 2010 | 4367 | 0.120 |
Why?
|
| Nursing Care | 1 | 2013 | 13 | 0.120 |
Why?
|
| Simvastatin | 1 | 2014 | 106 | 0.120 |
Why?
|
| Indians, North American | 1 | 2014 | 87 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 2 | 2015 | 383 | 0.120 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 24 | 0.120 |
Why?
|
| Clinical Coding | 1 | 2013 | 28 | 0.120 |
Why?
|
| Hospitalization | 3 | 2014 | 2083 | 0.110 |
Why?
|
| Cell Cycle Proteins | 4 | 2011 | 2045 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2011 | 607 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2009 | 1823 | 0.110 |
Why?
|
| Spheroids, Cellular | 4 | 2016 | 222 | 0.110 |
Why?
|
| Apoptosis | 3 | 2014 | 7591 | 0.110 |
Why?
|
| Mammary Glands, Animal | 2 | 2007 | 533 | 0.110 |
Why?
|
| Terminally Ill | 1 | 2014 | 91 | 0.110 |
Why?
|
| Jaw | 1 | 2012 | 20 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 854 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2016 | 624 | 0.110 |
Why?
|
| beta Catenin | 2 | 2007 | 688 | 0.110 |
Why?
|
| DNA-Binding Proteins | 5 | 2011 | 4821 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2010 | 1353 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 884 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 1085 | 0.110 |
Why?
|
| Women's Health | 2 | 2011 | 205 | 0.110 |
Why?
|
| Adolescent | 15 | 2015 | 31252 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 347 | 0.110 |
Why?
|
| Centromere Protein A | 1 | 2012 | 7 | 0.110 |
Why?
|
| Prostatic Neoplasms | 5 | 2016 | 5767 | 0.110 |
Why?
|
| MicroRNAs | 3 | 2016 | 2947 | 0.110 |
Why?
|
| Animals | 23 | 2016 | 59536 | 0.110 |
Why?
|
| Adenoma, Pleomorphic | 1 | 1992 | 63 | 0.110 |
Why?
|
| Residual Volume | 1 | 2012 | 11 | 0.110 |
Why?
|
| Lymphoscintigraphy | 1 | 2012 | 35 | 0.110 |
Why?
|
| Postoperative Complications | 5 | 2016 | 5542 | 0.110 |
Why?
|
| DNA Methylation | 3 | 1998 | 2669 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2012 | 8873 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2014 | 690 | 0.110 |
Why?
|
| Cell Dedifferentiation | 1 | 2012 | 96 | 0.110 |
Why?
|
| Emollients | 1 | 2011 | 12 | 0.110 |
Why?
|
| Petrolatum | 1 | 2011 | 11 | 0.100 |
Why?
|
| Pneumonectomy | 2 | 2014 | 831 | 0.100 |
Why?
|
| Propensity Score | 4 | 2016 | 750 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2015 | 431 | 0.100 |
Why?
|
| Histones | 4 | 2016 | 1466 | 0.100 |
Why?
|
| Ovary | 1 | 2016 | 668 | 0.100 |
Why?
|
| Lung | 5 | 2015 | 3151 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 5539 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2007 | 436 | 0.100 |
Why?
|
| Aftercare | 1 | 2013 | 259 | 0.100 |
Why?
|
| Osteosarcoma | 1 | 1999 | 929 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2013 | 441 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2016 | 3518 | 0.100 |
Why?
|
| Benzazepines | 1 | 2012 | 108 | 0.100 |
Why?
|
| Electronic Health Records | 2 | 2017 | 929 | 0.100 |
Why?
|
| Prevalence | 4 | 2016 | 3260 | 0.100 |
Why?
|
| Fees and Charges | 1 | 2011 | 16 | 0.100 |
Why?
|
| Erythropoietin | 2 | 1991 | 205 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 1450 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 128 | 0.100 |
Why?
|
| Orchiectomy | 2 | 2004 | 214 | 0.100 |
Why?
|
| Inhalation | 1 | 2011 | 42 | 0.100 |
Why?
|
| Valproic Acid | 1 | 2012 | 263 | 0.100 |
Why?
|
| Computer Simulation | 3 | 2017 | 1529 | 0.100 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2004 | 430 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2013 | 574 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 3 | 2012 | 3101 | 0.100 |
Why?
|
| Fibroblasts | 4 | 2012 | 1682 | 0.100 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 2195 | 0.100 |
Why?
|
| Data Collection | 1 | 2013 | 620 | 0.100 |
Why?
|
| National Health Programs | 1 | 2010 | 42 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.100 |
Why?
|
| Movement | 2 | 2011 | 556 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2011 | 78 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 4 | 1998 | 231 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2011 | 1391 | 0.090 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2012 | 203 | 0.090 |
Why?
|
| British Columbia | 1 | 2010 | 24 | 0.090 |
Why?
|
| Genotype | 4 | 2018 | 4109 | 0.090 |
Why?
|
| Drug Approval | 1 | 2011 | 178 | 0.090 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 168 | 0.090 |
Why?
|
| Monte Carlo Method | 3 | 2010 | 671 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2017 | 851 | 0.090 |
Why?
|
| Recurrence | 3 | 2009 | 4758 | 0.090 |
Why?
|
| RNA, Neoplasm | 2 | 2003 | 771 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 4638 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 666 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2015 | 717 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 155 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 306 | 0.090 |
Why?
|
| Drainage | 1 | 2012 | 416 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 291 | 0.090 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2009 | 73 | 0.090 |
Why?
|
| Patient Care Planning | 3 | 2011 | 297 | 0.090 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 229 | 0.090 |
Why?
|
| Obesity | 3 | 2012 | 2884 | 0.090 |
Why?
|
| Skin | 3 | 2010 | 1259 | 0.090 |
Why?
|
| Population Dynamics | 1 | 2009 | 42 | 0.090 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 918 | 0.090 |
Why?
|
| Models, Theoretical | 2 | 2009 | 785 | 0.090 |
Why?
|
| Integrin alpha6beta4 | 1 | 2009 | 31 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 538 | 0.080 |
Why?
|
| Esophageal Neoplasms | 2 | 2015 | 3168 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2008 | 65 | 0.080 |
Why?
|
| Receptors, Notch | 1 | 2012 | 383 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2016 | 316 | 0.080 |
Why?
|
| Oncology Service, Hospital | 1 | 2008 | 48 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2011 | 211 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2008 | 42 | 0.080 |
Why?
|
| Portal System | 1 | 2008 | 34 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1945 | 0.080 |
Why?
|
| Postoperative Period | 3 | 2007 | 665 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2009 | 355 | 0.080 |
Why?
|
| Cervix Uteri | 1 | 2010 | 253 | 0.080 |
Why?
|
| Models, Organizational | 1 | 2008 | 76 | 0.080 |
Why?
|
| Mice | 13 | 2016 | 34495 | 0.080 |
Why?
|
| Cell Line | 6 | 2014 | 5114 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2011 | 598 | 0.080 |
Why?
|
| Proton Therapy | 3 | 2019 | 1577 | 0.080 |
Why?
|
| Remission Induction | 5 | 2015 | 3569 | 0.080 |
Why?
|
| Ultrasonics | 1 | 2008 | 69 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2330 | 0.080 |
Why?
|
| Organ Size | 3 | 2018 | 690 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 980 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2008 | 142 | 0.080 |
Why?
|
| Pain Management | 1 | 2013 | 668 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 598 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2014 | 324 | 0.080 |
Why?
|
| Metal Nanoparticles | 1 | 2009 | 164 | 0.080 |
Why?
|
| Europe | 3 | 2017 | 649 | 0.080 |
Why?
|
| Gold | 1 | 2009 | 270 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2008 | 128 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 600 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2012 | 1863 | 0.080 |
Why?
|
| South America | 2 | 2017 | 52 | 0.080 |
Why?
|
| Genomic Imprinting | 2 | 1998 | 194 | 0.080 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 713 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 211 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 760 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 4971 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2012 | 492 | 0.070 |
Why?
|
| Hospitals | 1 | 2010 | 485 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 276 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 1077 | 0.070 |
Why?
|
| Age of Onset | 1 | 2009 | 827 | 0.070 |
Why?
|
| Base Sequence | 4 | 2013 | 4917 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 354 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 3343 | 0.070 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 460 | 0.070 |
Why?
|
| North America | 2 | 2017 | 314 | 0.070 |
Why?
|
| Boron | 2 | 1997 | 10 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2014 | 1270 | 0.070 |
Why?
|
| Social Support | 1 | 2009 | 560 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 280 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2008 | 298 | 0.070 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 735 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2011 | 1664 | 0.070 |
Why?
|
| Electrons | 2 | 2010 | 168 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2012 | 6150 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 361 | 0.070 |
Why?
|
| Rectus Abdominis | 1 | 2006 | 100 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2003 | 448 | 0.070 |
Why?
|
| Albumins | 1 | 2007 | 258 | 0.070 |
Why?
|
| Plants | 1 | 2005 | 62 | 0.070 |
Why?
|
| Cricetulus | 2 | 1997 | 205 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 1011 | 0.070 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 367 | 0.060 |
Why?
|
| Paget's Disease, Mammary | 1 | 2005 | 41 | 0.060 |
Why?
|
| Safety | 1 | 2007 | 465 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 3821 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 3 | 2015 | 183 | 0.060 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2017 | 85 | 0.060 |
Why?
|
| Observer Variation | 3 | 2014 | 671 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 2016 | 5395 | 0.060 |
Why?
|
| Vomiting | 1 | 2006 | 354 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 216 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 188 | 0.060 |
Why?
|
| Research Design | 2 | 2009 | 1544 | 0.060 |
Why?
|
| Cricetinae | 2 | 1997 | 706 | 0.060 |
Why?
|
| Neoplasm Grading | 3 | 2014 | 1742 | 0.060 |
Why?
|
| Thoracic Wall | 2 | 2004 | 183 | 0.060 |
Why?
|
| Nausea | 1 | 2006 | 525 | 0.060 |
Why?
|
| False Negative Reactions | 2 | 2015 | 275 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 485 | 0.060 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2014 | 231 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 4654 | 0.060 |
Why?
|
| Disease Progression | 3 | 2014 | 6682 | 0.060 |
Why?
|
| Hypertension | 1 | 2013 | 1503 | 0.060 |
Why?
|
| Overweight | 1 | 2007 | 484 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2004 | 175 | 0.060 |
Why?
|
| Benchmarking | 1 | 2006 | 273 | 0.060 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2004 | 88 | 0.060 |
Why?
|
| Sex Factors | 1 | 2009 | 2139 | 0.060 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 494 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 1756 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 3203 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 447 | 0.060 |
Why?
|
| Methotrexate | 1 | 2007 | 999 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 4320 | 0.060 |
Why?
|
| Alleles | 3 | 2007 | 2437 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2005 | 652 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2012 | 5637 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 4938 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2004 | 875 | 0.060 |
Why?
|
| Heterografts | 2 | 2016 | 733 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2003 | 1053 | 0.060 |
Why?
|
| tau Proteins | 1 | 2005 | 216 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4078 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2005 | 1620 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 1258 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 311 | 0.050 |
Why?
|
| Photons | 3 | 2013 | 507 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2005 | 253 | 0.050 |
Why?
|
| Culture Media, Conditioned | 2 | 2015 | 260 | 0.050 |
Why?
|
| Heterozygote | 2 | 2004 | 1020 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2015 | 2359 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 7222 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 665 | 0.050 |
Why?
|
| Spermatozoa | 1 | 2004 | 315 | 0.050 |
Why?
|
| Mediastinum | 2 | 2014 | 268 | 0.050 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2012 | 103 | 0.050 |
Why?
|
| Pyrimidinones | 2 | 2016 | 314 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2011 | 5270 | 0.050 |
Why?
|
| Sarcoma | 1 | 2012 | 1725 | 0.050 |
Why?
|
| Physicians | 1 | 2010 | 882 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 1 | 2002 | 249 | 0.050 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 70 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2000 | 6550 | 0.050 |
Why?
|
| Singlet Oxygen | 1 | 2021 | 8 | 0.050 |
Why?
|
| Phenol | 1 | 2021 | 19 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2002 | 226 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2002 | 229 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 860 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2004 | 6089 | 0.050 |
Why?
|
| Kidney | 1 | 2010 | 2146 | 0.050 |
Why?
|
| Watchful Waiting | 2 | 2014 | 289 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 435 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 639 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2012 | 409 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2021 | 108 | 0.050 |
Why?
|
| Preoperative Care | 3 | 2017 | 1529 | 0.050 |
Why?
|
| Drug Therapy | 2 | 2015 | 205 | 0.050 |
Why?
|
| Research | 1 | 2003 | 415 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 769 | 0.050 |
Why?
|
| Comet Assay | 1 | 2000 | 59 | 0.050 |
Why?
|
| Neoplasm Transplantation | 3 | 2012 | 1519 | 0.050 |
Why?
|
| Mucolipidoses | 1 | 2000 | 9 | 0.050 |
Why?
|
| Codon | 1 | 2000 | 241 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 2013 | 385 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2000 | 69 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2012 | 4307 | 0.050 |
Why?
|
| Fatigue | 1 | 2006 | 1239 | 0.050 |
Why?
|
| Arteries | 1 | 2001 | 274 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2023 | 348 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 5687 | 0.050 |
Why?
|
| Body Image | 1 | 2021 | 141 | 0.040 |
Why?
|
| Fat Necrosis | 2 | 2012 | 63 | 0.040 |
Why?
|
| Cell Proliferation | 4 | 2015 | 7226 | 0.040 |
Why?
|
| Mammary Arteries | 1 | 2000 | 64 | 0.040 |
Why?
|
| Heart Failure | 1 | 2013 | 2516 | 0.040 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2001 | 192 | 0.040 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2012 | 115 | 0.040 |
Why?
|
| Estrogens | 1 | 2003 | 751 | 0.040 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1999 | 48 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 605 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2001 | 2292 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 4557 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2003 | 1442 | 0.040 |
Why?
|
| Reference Values | 2 | 2012 | 1099 | 0.040 |
Why?
|
| Advisory Committees | 2 | 2009 | 203 | 0.040 |
Why?
|
| DNA | 2 | 2004 | 2693 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 291 | 0.040 |
Why?
|
| Pregnancy | 4 | 2009 | 7573 | 0.040 |
Why?
|
| Scattering, Radiation | 2 | 2010 | 316 | 0.040 |
Why?
|
| Institutionalization | 1 | 1997 | 13 | 0.040 |
Why?
|
| Isotopes | 1 | 1997 | 32 | 0.040 |
Why?
|
| Rabbits | 1 | 1999 | 957 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2017 | 67 | 0.040 |
Why?
|
| Lysosomes | 1 | 2000 | 347 | 0.040 |
Why?
|
| Hormones | 1 | 2018 | 266 | 0.040 |
Why?
|
| Time | 1 | 2017 | 178 | 0.040 |
Why?
|
| Mammary Glands, Human | 2 | 2010 | 184 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 7702 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2017 | 98 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2018 | 173 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Rats | 2 | 1997 | 6086 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 310 | 0.040 |
Why?
|
| Family | 1 | 2000 | 736 | 0.040 |
Why?
|
| Utilization Review | 1 | 2016 | 48 | 0.030 |
Why?
|
| G2 Phase | 1 | 2016 | 206 | 0.030 |
Why?
|
| Data Display | 1 | 2016 | 49 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 1999 | 387 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 1998 | 380 | 0.030 |
Why?
|
| Informed Consent | 2 | 2009 | 419 | 0.030 |
Why?
|
| Rett Syndrome | 1 | 1998 | 262 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 4744 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 256 | 0.030 |
Why?
|
| Supine Position | 1 | 2015 | 46 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 793 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 289 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 402 | 0.030 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2014 | 87 | 0.030 |
Why?
|
| Smoking | 3 | 2012 | 2440 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 862 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Radiation | 1 | 2014 | 20 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 1165 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 703 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 233 | 0.030 |
Why?
|
| Oxidants | 1 | 2014 | 49 | 0.030 |
Why?
|
| DNA Breaks, Single-Stranded | 1 | 2014 | 24 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 231 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 50 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 846 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 224 | 0.030 |
Why?
|
| Washington | 1 | 1994 | 70 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 1998 | 590 | 0.030 |
Why?
|
| Binding Sites | 2 | 2013 | 2171 | 0.030 |
Why?
|
| Colloids | 1 | 2013 | 34 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2014 | 126 | 0.030 |
Why?
|
| Thermoluminescent Dosimetry | 2 | 2006 | 77 | 0.030 |
Why?
|
| Hospices | 1 | 2014 | 51 | 0.030 |
Why?
|
| International Cooperation | 1 | 2015 | 323 | 0.030 |
Why?
|
| Radiobiology | 1 | 1994 | 56 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2014 | 217 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2014 | 240 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2015 | 388 | 0.030 |
Why?
|
| New York | 1 | 2013 | 104 | 0.030 |
Why?
|
| Cost Savings | 1 | 2014 | 123 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 299 | 0.030 |
Why?
|
| Florida | 1 | 2013 | 113 | 0.030 |
Why?
|
| United Kingdom | 1 | 1994 | 257 | 0.030 |
Why?
|
| Prone Position | 1 | 2013 | 56 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 126 | 0.030 |
Why?
|
| Radiology Department, Hospital | 1 | 1994 | 52 | 0.030 |
Why?
|
| Publishing | 1 | 2015 | 220 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 1910 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2013 | 234 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 472 | 0.030 |
Why?
|
| Neutrons | 1 | 1993 | 117 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 292 | 0.030 |
Why?
|
| Universities | 1 | 1994 | 160 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 294 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1997 | 1005 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 550 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2004 | 16273 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 107 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 343 | 0.030 |
Why?
|
| Rib Fractures | 1 | 2012 | 30 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 580 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2012 | 169 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2012 | 40 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1999 | 1678 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2007 | 2314 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2012 | 123 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 993 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2000 | 1589 | 0.030 |
Why?
|
| DNA Breaks | 1 | 2012 | 39 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2009 | 2074 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 99 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 238 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2013 | 844 | 0.030 |
Why?
|
| Polycomb-Group Proteins | 1 | 2011 | 42 | 0.030 |
Why?
|
| Pain | 2 | 2012 | 1658 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 1154 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2011 | 76 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2011 | 257 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 495 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2015 | 825 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 2944 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 626 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 698 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 749 | 0.020 |
Why?
|
| Physician Incentive Plans | 1 | 2010 | 20 | 0.020 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1994 | 285 | 0.020 |
Why?
|
| Taiwan | 1 | 2010 | 93 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 980 | 0.020 |
Why?
|
| Particle Accelerators | 2 | 2010 | 352 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2014 | 474 | 0.020 |
Why?
|
| Hematocrit | 1 | 1991 | 142 | 0.020 |
Why?
|
| Endosonography | 1 | 2014 | 536 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2009 | 1818 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 74 | 0.020 |
Why?
|
| Teratoma | 1 | 2012 | 236 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 557 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 694 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2011 | 160 | 0.020 |
Why?
|
| Models, Biological | 1 | 1999 | 3254 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 1085 | 0.020 |
Why?
|
| Proteins | 1 | 1999 | 1963 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2011 | 179 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2012 | 238 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 566 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 60 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 332 | 0.020 |
Why?
|
| Mutation | 4 | 2009 | 15179 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2011 | 245 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 519 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 423 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2012 | 322 | 0.020 |
Why?
|
| Tripartite Motif Proteins | 1 | 2009 | 55 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 585 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 636 | 0.020 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2014 | 406 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 1914 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 259 | 0.020 |
Why?
|
| Gonadotropins | 1 | 1989 | 50 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 709 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2054 | 0.020 |
Why?
|
| Breast Implants | 1 | 2014 | 391 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Denmark | 1 | 2008 | 48 | 0.020 |
Why?
|
| Postmenopause | 1 | 2010 | 378 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 852 | 0.020 |
Why?
|
| Body Burden | 1 | 2008 | 65 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 1869 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 269 | 0.020 |
Why?
|
| Keratins | 1 | 2009 | 330 | 0.020 |
Why?
|
| Infant | 3 | 2000 | 13310 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 99 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2009 | 220 | 0.020 |
Why?
|
| Respiration | 1 | 2010 | 447 | 0.020 |
Why?
|
| Morphogenesis | 1 | 2009 | 337 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 938 | 0.020 |
Why?
|
| Seroma | 1 | 2007 | 79 | 0.020 |
Why?
|
| Child | 5 | 2004 | 29154 | 0.020 |
Why?
|
| Health Resources | 1 | 2009 | 168 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1038 | 0.020 |
Why?
|
| Palliative Care | 1 | 2019 | 2037 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2008 | 219 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2010 | 351 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 1989 | 199 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 1688 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 1385 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 973 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 1547 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 509 | 0.020 |
Why?
|
| Esthetics | 1 | 2007 | 189 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 551 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 394 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 1382 | 0.020 |
Why?
|
| Thiotepa | 1 | 2006 | 118 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 202 | 0.020 |
Why?
|
| Carmustine | 1 | 2006 | 214 | 0.020 |
Why?
|
| Polyphenols | 1 | 2005 | 29 | 0.020 |
Why?
|
| Blood Component Removal | 1 | 2006 | 121 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 667 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2012 | 1146 | 0.020 |
Why?
|
| Estradiol | 1 | 1989 | 748 | 0.020 |
Why?
|
| Premenopause | 1 | 2005 | 131 | 0.020 |
Why?
|
| Anemia | 1 | 1991 | 689 | 0.020 |
Why?
|
| Infrared Rays | 1 | 2004 | 54 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 3033 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 2466 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2006 | 557 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 58 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 270 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2008 | 953 | 0.010 |
Why?
|
| Transcriptome | 1 | 2012 | 1859 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 2450 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 534 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 187 | 0.010 |
Why?
|
| Carcinoma, Ductal | 1 | 2005 | 145 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2002 | 159 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 198 | 0.010 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 1946 | 0.010 |
Why?
|
| Acute Disease | 1 | 2008 | 2422 | 0.010 |
Why?
|
| Contraindications | 1 | 2002 | 150 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 334 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3639 | 0.010 |
Why?
|
| Aging | 1 | 1991 | 1582 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 1399 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 869 | 0.010 |
Why?
|
| Catheterization | 1 | 2004 | 410 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 1648 | 0.010 |
Why?
|
| Hominidae | 1 | 2000 | 37 | 0.010 |
Why?
|
| Film Dosimetry | 1 | 2001 | 59 | 0.010 |
Why?
|
| Cathepsin A | 1 | 2000 | 4 | 0.010 |
Why?
|
| Carboxypeptidases | 1 | 2000 | 27 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 1162 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 882 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 211 | 0.010 |
Why?
|
| Patient Participation | 1 | 2004 | 446 | 0.010 |
Why?
|
| Stem Cells | 1 | 2007 | 1213 | 0.010 |
Why?
|
| COS Cells | 1 | 2000 | 377 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2002 | 487 | 0.010 |
Why?
|
| Medical Records | 1 | 2000 | 415 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 4053 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2002 | 268 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 997 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 3536 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1998 | 239 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1013 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2000 | 613 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2004 | 1129 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 792 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1998 | 177 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 1328 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1998 | 417 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 4757 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 974 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2000 | 1732 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1471 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2000 | 1152 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 1890 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 4233 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 5047 | 0.010 |
Why?
|
| Decision Making | 1 | 2000 | 1287 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 1960 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 1991 | 57 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1997 | 998 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1997 | 862 | 0.010 |
Why?
|
| Menotropins | 1 | 1989 | 7 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 130 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1989 | 241 | 0.010 |
Why?
|
| Ovarian Follicle | 1 | 1989 | 152 | 0.000 |
Why?
|
| Oocytes | 1 | 1989 | 414 | 0.000 |
Why?
|
| Pregnancy Outcome | 1 | 1989 | 643 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1991 | 1819 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1991 | 8223 | 0.000 |
Why?
|